Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 4/20 | 0.37 |
| ▸ | TK1 | P04183 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543584 | 0.96 | TYMS (0.39) | TYMSTK1 | |
| SCHEMBL548543 | 0.89 | TYMS (0.52) | TYMSTK1 | |
| SCHEMBL6854761 | 0.89 | TYMS (0.41) | TYMSTYMPTK1 | |
| SCHEMBL28475424 | 0.88 | TYMS (0.45) | TYMSTK1 | |
| SCHEMBL27508379 | 0.83 | TK1 (0.39) | TK1 | |
| SCHEMBL9947616 | 0.81 | TYMS (0.38) | TYMSTK1 | |
| SCHEMBL7040496 | 0.80 | TYMS (0.37) | TYMSTK1 | |
| Phosphoric Acid SCHEMBL7240883 | 0.80 | TYMP (0.43) | TYMPTK1 | |
| Phosphoric Acid SCHEMBL7243142 | 0.80 | TYMP (0.43) | TYMPTK1 | |
| Phosphoric Acid SCHEMBL8091428 | 0.77 | TYMP (0.42) | TYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092874-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20160176977-A1 | NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-8846043-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051838-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8562989-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1537140-B1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120142072-A1 | SOLUBLE PROTEIN AND UTILIZATION OF THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8110660-B2 | Soluble ENPP4 protein | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110287016-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7977062-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2302041-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | Agensys, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100240583-A1 | SOLUBLE PROTEIN AND UTILIZATION OF THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100158934-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-1813671-A1 | SOLUBLE PROTEIN AND UTILIZATION OF THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7226594-B2 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20030206905-A1 | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer | AGENSYS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003040340-A9 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | AGENSYS INC (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287016-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TYMP 1066/4885TK1 1759/4885 |
| US-20100158934-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TYMP 1066/4885TK1 1759/4885 |
| US-20140051838-A1 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER | DCLRE1B, PABPC1, PABPC4 | TYMS 1468/4885TYMP 1066/4885TK1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.